R Rodia1, P E Meloni1, V Ruggiero1, S Mariotti1, C Mascia1, C Balestrieri2, G Serra2, M Conti2, M Loi2, F Pes2, S Onali2, A Perra3, R Littera4, F Velluzzi1, L Chessa2, F Boi5. 1. Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Azienda Ospedaliero-Universitaria di Cagliari, SS 554, Bivio per Sestu, 09042, Monserrato, Cagliari, Italy. 2. Centre of Liver Diseases, Department of Medical Sciences and Public Health, University of Cagliari, Azienda Ospedaliero-Universitaria di Cagliari, SS 554, Bivio per Sestu, 09042, Monserrato, Cagliari, Italy. 3. Unit of Oncology and Molecular Pathology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. 4. Complex Structure of Medical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Cagliari, Italy. 5. Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Azienda Ospedaliero-Universitaria di Cagliari, SS 554, Bivio per Sestu, 09042, Monserrato, Cagliari, Italy. francesco.boi@unica.it.
Abstract
PURPOSE: It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may induce thyroid alterations. METHODS: A total of 113 HCV patients, subdivided at the time of the enrollment in naïve group (n = 64) and in IFN-α group (n = 49) previously treated with pegylated interferon-α and ribavirin, were evaluated for thyroid function and autoimmunity before and after 20-32 weeks of DAAs. RESULTS: Before starting DAAs, a total of 8/113 (7.1%) patients showed Hashimoto's thyroiditis (HT) all belonging to IFN-α group (8/49, 16.3%), while no HT cases were found in the naïve group. Overall, 7/113 (6.2%) patients were hypothyroid: 3/64 (4.7%) belonging to naïve group and 4/49 (8.2%) to IFN-α group. Furthermore, a total of 8/113 patients (7.1%) showed subclinical hyperthyroidism: 2/64 (3.1%) were from naïve group and 6/49 (12.2%) from IFN-α group. Interestingly, after DAAs therapy, no new cases of HT, hypothyroidism and hyperthyroidism was found in all series, while 6/11 (54.5%) patients with non-autoimmune subclinical thyroid dysfunction became euthyroid. Finally, the only association between viral genotypes and thyroid alterations was genotype 1 and hypothyroidism. CONCLUSIONS: This study supports evidence that DAAs have a limited or missing influence on thyroid in patients with HCV-related diseases. Moreover, it provides preliminary evidence that subclinical non-autoimmune thyroid dysfunction may improve after HCV infection resolution obtained by DAAs.
PURPOSE: It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may induce thyroid alterations. METHODS: A total of 113 HCV patients, subdivided at the time of the enrollment in naïve group (n = 64) and in IFN-α group (n = 49) previously treated with pegylated interferon-α and ribavirin, were evaluated for thyroid function and autoimmunity before and after 20-32 weeks of DAAs. RESULTS: Before starting DAAs, a total of 8/113 (7.1%) patients showed Hashimoto's thyroiditis (HT) all belonging to IFN-α group (8/49, 16.3%), while no HT cases were found in the naïve group. Overall, 7/113 (6.2%) patients were hypothyroid: 3/64 (4.7%) belonging to naïve group and 4/49 (8.2%) to IFN-α group. Furthermore, a total of 8/113 patients (7.1%) showed subclinical hyperthyroidism: 2/64 (3.1%) were from naïve group and 6/49 (12.2%) from IFN-α group. Interestingly, after DAAs therapy, no new cases of HT, hypothyroidism and hyperthyroidism was found in all series, while 6/11 (54.5%) patients with non-autoimmune subclinical thyroid dysfunction became euthyroid. Finally, the only association between viral genotypes and thyroid alterations was genotype 1 and hypothyroidism. CONCLUSIONS: This study supports evidence that DAAs have a limited or missing influence on thyroid in patients with HCV-related diseases. Moreover, it provides preliminary evidence that subclinical non-autoimmune thyroid dysfunction may improve after HCV infection resolution obtained by DAAs.
Authors: Paul Y Kwo; Fred Poordad; Armen Asatryan; Stanley Wang; David L Wyles; Tarek Hassanein; Franco Felizarta; Mark S Sulkowski; Edward Gane; Benedict Maliakkal; J Scott Overcash; Stuart C Gordon; Andrew J Muir; Humberto Aguilar; Kosh Agarwal; Gregory J Dore; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa Journal: J Hepatol Date: 2017-04-13 Impact factor: 25.083
Authors: Massimo Puoti; Graham R Foster; Stanley Wang; David Mutimer; Edward Gane; Christophe Moreno; Ting Tsung Chang; Samuel S Lee; Rui Marinho; Jean-Francois Dufour; Stanislas Pol; Christophe Hezode; Stuart C Gordon; Simone I Strasser; Paul J Thuluvath; Zhenzhen Zhang; Sandra Lovell; Tami Pilot-Matias; Federico J Mensa Journal: J Hepatol Date: 2018-03-16 Impact factor: 25.083
Authors: Edward Gane; Fred Poordad; Stanley Wang; Armen Asatryan; Paul Y Kwo; Jacob Lalezari; David L Wyles; Tarek Hassanein; Humberto Aguilar; Benedict Maliakkal; Ran Liu; Chih-Wei Lin; Teresa I Ng; Jens Kort; Federico J Mensa Journal: Gastroenterology Date: 2016-07-25 Impact factor: 22.682
Authors: A Imagawa; N Itoh; T Hanafusa; Y Oda; M Waguri; J Miyagawa; N Kono; M Kuwajima; Y Matsuzawa Journal: J Clin Endocrinol Metab Date: 1995-03 Impact factor: 5.958
Authors: Yong Hwang; Won Kim; So Young Kwon; Hyung Min Yu; Jeong Han Kim; Won Hyeok Choe Journal: Korean J Intern Med Date: 2015-10-30 Impact factor: 2.884